Cancer and Cell Therapy · us
Engineered TIL therapy without systemic IL-2 shows early responses in refractory melanoma trials
Giving cancer-fighting cells their own drug-regulated growth signal may reduce cell therapy’s reliance on externally administered cytokines. At the recommended dose, amsoki-cel produced tumor responses in 10 of 15 patients, but the small trials also recorded serious adverse events.
When immune checkpoint inhibitors can no longer control melanoma, restoring immune cell activity presents a treatment challenge. A study published in *Nature Medicine* on November 3 proposes a new approach: engineering patients’ own cancer-fighting cells and using a drug to regulate their growth signals.
The investigational therapy, amsoki-cel, is a tumor-infiltrating lymphocyte (TIL) therapy in which immune cells are removed from tumors, expanded, and infused back into patients. The researchers added regulatable membrane-bound interleukin-15 (IL-15), eliminating the need for systemic IL-2 administration during the treatment regimen.
The regulating agent is acetazolamide: the drug stabilizes the engineered protein, allowing IL-15 to appear on the cell surface. This design aims to support cell expansion and persistence; patients still require lymphodepleting chemotherapy before the cells are infused.
The research covered two single-arm trials, with a total of 37 patients treated. Among 15 patients who received the recommended phase 2 dose, 10 achieved an objective response, including 2 complete responses. These 15 patients comprised 6 from phase 1 and 9 from phase 2; this was not an independent, large phase 2 result.
Safety also warrants attention. Among the 37 patients, 10 experienced serious treatment-emergent adverse events; common events of grade 3 or higher included cytopenias. These events occurred during the overall treatment regimen and cannot all be attributed to the engineered cells themselves.
One of the earliest patients treated experienced rapid lymphocyte expansion and edema in previously irradiated brain metastases, prompting the team to reduce the dose and modify the protocol. Eliminating systemic IL-2 does not mean treatment risks have disappeared.
The results still come from small studies without control groups, and the pooled analysis was conducted post hoc. Whether tumor shrinkage is durable, whether survival improves, and whether the therapy offers safety advantages over existing treatments all require confirmation in subsequent trials.